Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD

NCT00929708 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00929708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00929708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
March 31, 2010
Enrollment
329 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

copd